<SEC-DOCUMENT>0001193125-21-219855.txt : 20210824
<SEC-HEADER>0001193125-21-219855.hdr.sgml : 20210824
<ACCEPTANCE-DATETIME>20210720200458
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-21-219855
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Candel Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001841387
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				522214851
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		617-916-5445

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 450
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Candel Therapeutics, Inic.
		DATE OF NAME CHANGE:	20210120
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Response Letter</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g120909g0714074305890.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin&nbsp;Procter&nbsp;<SMALL>LLP</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100&nbsp;Northern&nbsp;Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman" ALIGN="right">July&nbsp;20, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>VIA EDGAR </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange
Commission &nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mail Stop 4561 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: David Gessert and Celeste Murphy </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Candel Therapeutics, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amendment No.&nbsp;1 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed July&nbsp;16, 2021 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">File <FONT STYLE="white-space:nowrap">No.&nbsp;333-257444</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Gessert and Ms.&nbsp;Murphy: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter is
submitted on behalf of Candel Therapeutics, Inc. (the &#147;<B>Company</B>&#148;) in response to the comments of the staff of the Division of Corporation Finance (the &#147;<B>Staff</B>&#148;) of the U.S. Securities and Exchange Commission (the
&#147;<B>Commission</B>&#148;) with respect to the Company&#146;s Amendment No.&nbsp;1 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> filed on July&nbsp;16, 2021 (the &#147;<B>Registration Statement</B>&#148;), as set
forth in the Staff&#146;s letter, dated July&nbsp;19, 2021, addressed to Paul Peter Tak, M.D., Ph.D. (the &#147;<B>Comment Letter</B>&#148;). In response to the comment set forth in the Comment Letter, the company has revised the Registration
Statement and is publicly filing Amendment No.&nbsp;2 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B>Amended</B> <B>Registration Statement</B>&#148;), together with this response letter. The Amended
Registration Statement also contains certain additional updates and revisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For reference purposes, the text of the Comment Letter has been reproduced
herein with a response below the numbered comment. For your convenience, we have italicized the reproduced Staff comment from the Comment Letter. The page reference in the description of the Staff&#146;s comment refers to the Registration Statement,
and the exhibit reference in the response refers to the Amended Registration Statement. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Amended Registration Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July 20, 2021 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The response provided herein is based upon information provided to Goodwin Procter LLP by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Amendment No.&nbsp;1 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Executive Officers and Directors,
page&nbsp;148 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note your disclosure on page 151 that Diem Nguyen will serve as a member of your board of directors upon
the effectiveness of this registration statement. Please file a written consent of Dr.</I><I></I><I>&nbsp;Nguyen to be named in such capacity as an exhibit to your registration statement. Refer to Rule 438 of Regulation C for guidance.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RESPONSE: </B>The Company respectfully advises the Staff that it has filed the written consent of Dr.&nbsp;Nguyen as Exhibit 99.1 of
the Amended Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you should have any questions regarding the enclosed matters, please contact the undersigned at
(617) <FONT STYLE="white-space:nowrap">570-1447.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William Collins</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William Collins, Esq.</P></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Paul Peter Tak, M.D., Ph.D., Candel Therapeutics, Inc.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>John Canepa, Candel Therapeutics, Inc.</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Robert E. Puopolo, Goodwin Procter LLP</I> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nicole Daley, Goodwin Procter LLP</I> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g120909g0714074305890.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g120909g0714074305890.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  M ,@# 2(  A$! Q$!_\0
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@'",11H@/)"J!3LT9H 9+#%, )(T<#IN4'%%/HH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
